Results 181 to 190 of about 49,721 (234)

Microbial Signals in Cancer: Dissecting Host–Microbiota–Tumor Interactions and Potential Therapeutic Strategy

MedComm, Volume 7, Issue 9, September 2026.
Microbial signals from gut and tumor‐resident bacteria, fungi, viruses, and bacteriophages reshape immune and metabolic networks within the tumor microenvironment, thereby influencing cancer progression, treatment response. Therapeutic modulations, including dietary interventions, probiotics, antibiotics, fecal microbiota transplantation, engineered ...
Juan Lu, Mengjuan Xuan, Liang Yu, Zhongyang Xie, Qingfei Chu, Shihui Wei, Tuokai Wang, Chen Xue, Lanjuan Li   +8 more
wiley   +1 more source

Nanoparticle‐Mediated Therapy for Glioma: Advances and Prospects

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Various nanocarriers, including liposomes, dendrimers, exosomes and gold nanoparticles, are designed to penetrate the blood‐brain barrier and deliver chemotherapy, radiotherapy, immunotherapy, gene therapy, phototherapy, magnetic hyperthermia and sonodynamic therapy for glioma.
Wenqian Jiang, Jing Fei, Rangrang Fan, Haifeng Chen, Liangxue Zhou, Gang Guo   +5 more
wiley   +1 more source

Nitric Oxide in Cancer: Mechanisms, Dual Role, and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Nitric oxide exerts concentration‐dependent dual roles in cancer, functioning as either a tumor promoter or suppressor. This review comprehensively examines NO's multifaceted regulation of tumor biology, including S‐nitrosylation signaling, metabolic reprogramming, immunemodulation, and therapy resistance, and highlights emerging therapeutic strategies
Jia Shao, Honghua Zhang, Jingyu Chen, Ziyu Qian, Ning Zhang, Yihua Zhang, Hui Ye, Jianbing Wu, Zhangjian Huang   +8 more
wiley   +1 more source

Oxysterols in Cancer: From Biosynthesis and Pathophysiology to Targeted Therapeutics

MedComm – Oncology, Volume 5, Issue 3, September 2026.
Mechanisms by which oxysterol targeting may enhance immunotherapy efficacy. This figure illustrates potential metabolic interventions that may improve antitumor immunity by modulating oxysterol related pathways. CH25H modulation may reduce 25‐HC accumulation, promote the conversion of cold tumors into hot tumors, and increase T cell infiltration and PD‐
Haili Shang, Yongsheng Li
wiley   +1 more source

Carbon Dots in Breast Cancer Theranostics: Structure–Property Relationships, Mechanisms, and Translational Insights

MedComm – Oncology, Volume 5, Issue 3, September 2026.
This review provides a comprehensive overview of carbon dot–based technologies for breast cancer diagnosis and therapy, including their toxicity profiles. It outlines how C‐dots function as a versatile platform—serving simultaneously as therapeutic agents, drug‐delivery vehicles, and bioimaging tools. The article also highlights cutting‐edge approaches
Srija Sur, Pegah Varamini
wiley   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB–IIIA Non‐Small‐Cell Lung Cancer: Phase 2 neoSCORE Trial

Cancer Science, Volume 117, Issue 9, Page 2509-2520, September 2026.
Kaplan–Meier survival curves comparing two‐cycle versus three‐cycle neoadjuvant sintilimab plus chemotherapy. (A) Disease‐free survival (DFS). (B) Overall survival (OS). CI, confidence interval; HR, hazard ratio; NR, not reached. ABSTRACT The optimal number of neoadjuvant chemoimmunotherapy cycles for resectable non‐small cell lung cancer (NSCLC ...
Miner Shao, Jie Yao, Lufeng Zhao, Ling Zhu, Baizhou Li, Lili Li, Bangyi Zhou, Yixin Zhang, Huiying Liu, Xiaoke Chen, Zuqun Wu, Zexin Chen, Junqiang Fan, Fuming Qiu   +13 more
wiley   +1 more source

Advancements in Immunotherapy for Lung Cancer: A Meta‐Analysis of Clinical Trial Outcomes

The Clinical Respiratory Journal, Volume 20, Issue 9, September 2026.
The graphical abstract presents a meta‐analysis of randomized controlled trials (RCTs) associating immune checkpoint inhibitors (ICIs) with or without chemotherapy versus chemotherapy alone for adults with advanced or metastatic non–small cell lung cancer (NSCLC) ABSTRACT Immune checkpoint inhibitors (ICIs) have changed therapeutic selections for ...
Yingjie Jiao, Yan Zhao
wiley   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Mitochondrial Transfer From Satellite Glial Cells to Neurons via Tunneling Nanotubes: A New Protective Axis for Peripheral Neuropathy

MedComm – Future Medicine, Volume 5, Issue 3, September 2026.
Qing Ye, Jialuoyang Chen, Guihua Wei
wiley   +1 more source